Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07609225 · ClinicalTrials.gov registry record · Early Phase 1
Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy
A Early Phase 1 study, sponsored by University of Wisconsin, Madison.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT07609225 is a Early Phase 1 study that has not yet begun recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 15 participants.
The verdict
NCT07609225, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Wisconsin, Madison.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study compares two different imaging procedures to each other, one using positron emission tomography (PET) with fluorothymidine F-18 (FLT) (FLT PET for short), and the other using chemical shift-encoded (CSE) magnetic resonance imaging (MRI) or CSE-MRI for short, to determine specifically if CSE-MRI is as accurate as FLT PET in telling the difference between active and inactive marrow. The best way to do the comparison between the two imaging procedures is if they are done at the same time on the same patient. This is possible with use of a scanner at the University of Wisconsin Hospitals and Clinics (UW Health), the GE SIGNA PET/MR scanner. The prediction is that CSE-MRI as accurate as FLT at telling the difference between active and inactive marrow in patients with metastatic prostate cancer, and that is the primary reason for this study. 15 participants will be enrolled and on study for up to 14 months.
Interventions
- DRUG 3'-Deoxy-3'-[18F]-fluorothymidine
- DEVICE Chemical-shift-encoded MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-07 |
| Est. Completion | 2029-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07609225
The ClinicalTrials.gov registry entry for NCT07609225 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 3'-Deoxy-3'-[18F]-fluorothymidine is the first listed.
NCT07609225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07609225 about?
NCT07609225 is a clinical study titled "Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy". This study compares two different imaging procedures to each other, one using positron emission tomography (PET) with fluorothymidine F-18 (FLT) (FLT PET for short), and the other using chemical shift-encoded (CSE) magnetic resonance imaging (MRI) or CSE-MRI for short, to determine specifically if C...
What is the current status of trial NCT07609225?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2026-07. Estimated completion is 2029-07.
What interventions are being tested in trial NCT07609225?
The interventions under investigation include: 3'-Deoxy-3'-[18F]-fluorothymidine (DRUG), Chemical-shift-encoded MRI (DEVICE).
Who is sponsoring clinical trial NCT07609225?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.